Similar articles

• Anti-vascular endothelial growth factor therapy for subfoveal choroidal neovascularization secondary to age-related macular degeneration: phase II study results.

  Eyetech Study Group. Eyetech Study Group. Ophthalmology. 2003 May;110(5):979-86. doi: 10.1016/S0161-6420(03)00085-X. Ophthalmology. 2003. PMID: 12750101 Clinical Trial.
• [New therapeutic approaches to age dependent macular degeneration].

  Holz FG. Holz FG. Ophthalmologe. 2003 Feb;100(2):90-1. doi: 10.1007/s00347-003-0786-2. Ophthalmologe. 2003. PMID: 12653082 German. No abstract available.
• Re: development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration.

  Ziemssen F, Heiduschka P, Schraermeyer U; Tübingen Bevacizumab Study Group. Ziemssen F, et al. Retina. 2007 Oct;27(8):1154-6; author reply 1156-8. doi: 10.1097/IAE.0b013e3180ca7daf. Retina. 2007. PMID: 18040264 No abstract available.
• [Pathogenesis of choroidal neovascularization. Old concepts, new questions].

  Fauser S, Engelmann K, Krohne TU, Lappas A, Kirchhof B, Joussen AM. Fauser S, et al. Ophthalmologe. 2003 Apr;100(4):300-5. doi: 10.1007/s00347-003-0802-6. Ophthalmologe. 2003. PMID: 12682762 Review. German.
• Anti-vascular endothelial growth factor strategies for the treatment of choroidal neovascularization from age-related macular degeneration.

  Barouch FC, Miller JW. Barouch FC, et al. Int Ophthalmol Clin. 2004 Summer;44(3):23-32. doi: 10.1097/00004397-200404430-00005. Int Ophthalmol Clin. 2004. PMID: 15211174 Review. No abstract available.